Fadi Haddad 🇺🇸
Day 2 | Hematology Track
Precisive Approach toward Managing Ph+ ALL
Day 2 | Hematology Track
Untangling the knots in Ph-like ALL
Day 3 | | Hematology Track
MyeloMATCH / Clinical Paradigms in Clinical Trials
Day 2 | | Hematology Track
Untangling the knots in Ph-like ALL
Day 2 | | Hematology Track
DLBLC molecular subtypes, are we ready for individualized treatments?
Day 2 | | Hematology Track
Updates in T-Cell lymphoma treatment
Day 2 | | Hematology Track
The role of radiotherapy in lymphoma treatment, does it still have a role in the era of targeted treatments?
Day 2 | | Hematology Track
Bispecific Antibodies, interesting combinations and interesting outcomes
Day 2 | | Hematology Track
New EHA-EMN 2025 MM guidelines: The use and positioning of new therapeutic drug classes
Day 2 | | Hematology Track
How to manage high risk disease; plasma cell leukemia & extramedullary disease
Day 2 | | Hematology Track
Novel approaches to newly diagnosed MM
Day 2 | | Hematology Track
Defining high-risk disease in MM
Day 2 | | Hematology Track
Follicular lymphoma
Day 2 | | Hematology Track
Sequencing Therapy in CLL
Day 2 | | Hematology Track
Nodular lymphocytes predominate Hodgkin lymphoma
Day 2 | | Hematology Track
BTK targeting in lymphoma
Day 2 | | Hematology Track
Updates in the management of Hodgkin lymphoma